Bannayan-Riley-Ruvalcaba Syndrome (BRRS)

Bannayan-Riley-Ruvalcaba syndrome (BRRS) is a rare genetic condition. It belongs to a family of disorders called PTEN hamartoma tumor syndrome (PHTS). The main features are a very large head (macrocephaly), many benign growths called hamartomas (for example lipomas under the skin and polyps in the intestine), and small dark spots on the penis in males (genital lentigines). Many people also have developmental delay or learning problems. BRRS is usually caused by a change (pathogenic variant) in the PTEN gene, which is a tumor-suppressor gene that controls cell growth. Because PTEN is not working correctly, tissues can overgrow and make hamartomas; lifetime risks of certain cancers are increased across the PHTS spectrum. Orpha+3NCBI+3MedlinePlus+3

BRRS is autosomal dominant. This means a single altered PTEN gene can cause the condition. The altered gene can be inherited from a parent or happen as a new (de novo) change in the child. Some people have mosaicism (the DNA change is present in some cells but not others), which can make features milder or mixed. BRRS overlaps clinically with Cowden syndrome and other PHTS diagnoses; they share the same gene and many findings, but BRRS often starts in childhood with macrocephaly, lipomas, polyps, and genital lentigines. NCBI+1

Bannayan–Riley–Ruvalcaba syndrome (BRRS) is a rare, inherited overgrowth condition caused most often by a harmful change (pathogenic variant) in the PTEN gene. BRRS belongs to the PTEN hamartoma tumor syndrome (PHTS) family, which also includes Cowden syndrome and a few related conditions. People with BRRS usually have a large head size (macrocephaly), multiple benign growths (hamartomas)—often in the bowel—and multiple lipomas (fatty lumps). Males may have penile lentigines (dark freckles). Developmental differences can be present. BRRS itself is not a cancer, but because it sits under the PHTS umbrella, it carries elevated risks for certain cancers over a lifetime, so planned screening is important. NCBI+2MedlinePlus+2

PTEN is a tumor-suppressor gene. Its protein helps control cell growth by “braking” the PI3K/AKT/mTOR signaling pathway. When PTEN is damaged, the brake is weaker, so benign overgrowths (hamartomas) can form in many tissues; over many years, cancer risks also rise. In BRRS, most patients have a germline (inherited) PTEN variant, often autosomal dominant; some variants arise de novo (new in the child). Mosaicism (the variant in some cells but not others) can occur. NCBI+2Nature+2

Other names

BRRS has been described in the past by several names. You might see: “PTEN hamartoma tumor syndrome—Bannayan-Riley-Ruvalcaba type,” “Bannayan-Zonana syndrome,” “Riley-Smith syndrome,” and “Ruvalcaba-Myhre-Smith syndrome.” All of these refer to the same clinical spectrum linked to PTEN. NCBI+1

Types

Doctors do not use strict “official subtypes” within BRRS the way they do for some other conditions. Clinicians usually group people by dominant features to guide care and surveillance. Common practical groupings are:
(1) Classic childhood-onset BRRS (macrocephaly, lipomas, intestinal hamartomas, genital lentigines).
(2) Polyposis-predominant BRRS (many GI hamartomatous polyps, sometimes bleeding or intussusception).
(3) Neurodevelopment-predominant BRRS (macrocephaly with developmental delay and/or autism features).
(4) Vascular-anomaly-associated BRRS (capillary malformations/hemangiomas/AVMs as part of PHTS “minor criteria”).
(5) BRRS with overlapping Cowden features (thyroid nodules/goiter, breast/endometrial/renal risks typical of PHTS).
These “types” reflect patterns along the single genetic spectrum of PHTS rather than separate diseases. Nature+3NCBI+3PMC+3

Causes

1. PTEN loss-of-function sequence variants (missense, nonsense, splice). These changes reduce PTEN protein activity. NCBI

2. Small insertions/deletions in PTEN that disrupt the protein. NCBI

3. Large deletions/duplications involving PTEN (copy-number changes). Some patients with negative sequencing have exon-level deletions. ERN ITHACA

4. Promoter or regulatory variants that lower PTEN expression. (Described within broader PHTS literature.) NCBI

5. De novo PTEN variants (new in the child). NCBI

6. Inherited PTEN variants from an affected parent (autosomal dominant). NCBI

7. Mosaic PTEN variants (present in some tissues only), leading to variable features. NCBI

8. PTEN haploinsufficiency (one working copy is not enough, causing overgrowth and hamartomas). NCBI

9. PI3K/AKT/mTOR pathway dysregulation downstream of PTEN, driving cell growth and hamartomas. NCBI

10. Second-hit events in local tissues that can enlarge specific hamartomas. (General tumor suppressor biology within PTEN literature.) NCBI

11. Developmental overgrowth mechanisms that start in fetal life, explaining high birth weight and macrocephaly. MedlinePlus

12. Abnormal vascular development causing hemangiomas or vascular malformations as minor PHTS criteria. PMC

13. Aberrant adipose tissue growth leading to multiple lipomas. PMC

14. Intestinal mucosal overgrowth forming hamartomatous polyps. NCBI

15. Cutaneous melanocytic change causing genital lentigines (speckled penis). MedlinePlus

16. Thyroid follicular overactivity and nodularity in the PHTS spectrum. Nature

17. Neuronal/gliial growth control changes contributing to macrocephaly and neurodevelopmental issues. NCBI

18. Renal epithelial proliferation raising lifetime renal cell carcinoma risk in PHTS adults. Nature

19. Breast/endometrial epithelial overgrowth risks in PHTS adults (important for family counseling). Nature

20. Genotype-phenotype variability: different PTEN variants and backgrounds lead to broad clinical diversity within BRRS. Nature

Symptoms and signs

1. Macrocephaly (head size above normal for age). Often present from birth or early infancy. MedlinePlus

2. Multiple lipomas (soft, mobile, fatty lumps under the skin). They are benign but can be numerous. PMC

3. Genital lentigines in males (many small, dark pigmented spots on the penis). This is very suggestive of BRRS. MedlinePlus

4. Hamartomatous intestinal polyps (can cause pain, bleeding, anemia, or intussusception). NCBI+1

5. Developmental delay and learning difficulties; sometimes features of autism spectrum. rarediseases.info.nih.gov

6. High birth weight or length (overgrowth traits in infancy). MedlinePlus

7. Hemangiomas/vascular malformations (capillary or venous anomalies). PMC

8. Thyroid nodules or goiter; rarely childhood thyroid cancer, with greater risks in adulthood. Nature+1

9. Skin and mucous membrane findings (trichilemmomas and oral papillomas are more Cowden-like but overlap in PHTS). NCBI

10. Headaches or neurologic symptoms (rarely related to cerebellar dysplastic gangliocytoma—Lhermitte-Duclos—in the PHTS spectrum). NCBI

11. Abdominal pain, diarrhea, or bleeding from GI polyps. NCBI

12. Anemia (often iron-deficiency due to chronic GI blood loss from polyps). NCBI

13. Cosmetic or mechanical discomfort from many lipomas. PMC

14. Behavioral challenges connected to neurodevelopmental differences. rarediseases.info.nih.gov

15. Family history of macrocephaly, PHTS features, or early-onset cancers in a first-degree relative. NCBI

Diagnostic tests

A) Physical examination (at the bedside)

1. Head circumference measurement plotted on age/sex growth charts to confirm macrocephaly. MedlinePlus

2. General growth assessment (weight/length/BMI) to document overgrowth traits. MedlinePlus

3. Full skin exam to detect lipomas, hemangiomas, and mucocutaneous findings. PMC+1

4. Focused genital exam in males to look for penile lentigines (a classic BRRS clue). MedlinePlus

5. Thyroid palpation to feel for nodules or goiter as part of PHTS features. Nature

B) “Manual” clinical assessments (no machines, hands-on or paper-based)

6. Detailed family history (three-generation pedigree) for macrocephaly, BRRS/PHTS traits, and early cancers. NCBI

7. Neurologic and developmental evaluation (milestones, speech, behavior, school performance). rarediseases.info.nih.gov

8. Abdominal exam for tenderness, masses, or signs of GI bleeding. NCBI

9. Beighton hyperlaxity score if joint laxity or soft-tissue overgrowth is suspected in the phenotype (contextual musculoskeletal screening within PHTS clinical genetics practice). NCBI

10. Nutritional and symptom questionnaires (fatigue from anemia, stool frequency, rectal bleeding) to triage GI work-up. NCBI

C) Laboratory and pathological tests

11. Germline PTEN testing (the key test): sequencing plus deletion/duplication analysis (e.g., NGS + MLPA). Confirms diagnosis when a pathogenic variant is found; mosaicism may need specialized assays. NCBI+2Orpha+2

12. Complete blood count (CBC) and iron studies to look for anemia from GI blood loss. NCBI

13. Thyroid function tests (TSH, free T4) if there are nodules, goiter, or growth concerns. Nature

14. Stool tests (occult blood; stool alpha-1 antitrypsin if protein-losing enteropathy is suspected). Scientific Archives

15. Pathology review of removed polyps to confirm hamartomatous type and rule out dysplasia. NCBI

D) Electrodiagnostic tests

16. EEG if there are seizures or concerning events in a child with macrocephaly/neurodevelopmental issues (used case-by-case). NCBI

17. Nerve conduction studies/EMG only if there are neuromuscular symptoms (not routine; used for specific complaints). NCBI

E) Imaging and endoscopic tests

18. Brain MRI if symptoms suggest structural issues; also to evaluate for Lhermitte-Duclos in PHTS spectrum when clinically indicated. PMC+1

19. Thyroid ultrasound (age-appropriate surveillance in PHTS; pediatrics often start by ~age 7). Children’s Hospital of Philadelphia

20. GI endoscopy/colonoscopy to find and treat hamartomatous polyps when there is bleeding, anemia, pain, or intussusception. Additional abdominal/renal ultrasound is considered for broader PHTS surveillance planning in families. NCBI+2Scientific Archives+2

Non-pharmacological treatments

There is no single curative drug for BRRS. Care is multidisciplinary: genetics, gastroenterology, surgery, dermatology, endocrinology/thyroid, nephrology/urology, neurology, developmental pediatrics/therapy, psychology, and primary care. Treatment focuses on removing or monitoring troublesome hamartomas, managing symptoms/complications, and cancer screening. NCBI

1) Genetic counseling and family testing. Explains inheritance, clarifies who else may benefit from testing, and builds a personalized surveillance plan. Early identification improves prevention. NCBI

2) Structured cancer surveillance program. A written schedule (e.g., thyroid US, breast MRI/mammography as appropriate, skin and renal checks) coordinated by one clinic to avoid missed screenings. Nature+1

3) Developmental evaluation & therapies. Early referral for speech/occupational/physical therapy supports gross/fine motor and communication skills; individualized education plans (IEPs) aid school function. MedlinePlus

4) Nutrition & bowel care plan. For polyp-related bleeding, anemia, or altered motility: fiber titration, iron-rich diet as needed, hydration, and dietitian support reduce symptoms between endoscopic treatments. NCBI

5) Dermatology monitoring & sun protection. Regular skin checks help track mucocutaneous lesions and detect melanoma earlier; sunscreen and clothing lower UV-related risks. Nature

6) Targeted physical therapy. Joint laxity, hypotonia, or overgrowth-related imbalance respond to individualized strengthening and proprioceptive training; falls and pain often lessen. NCBI

7) Mental health support. Coping with a chronic genetic syndrome can be stressful; counseling improves adherence to lifelong screening and quality of life. NCBI

8) Sleep screening. Large tonsils, macrocephaly, or hypotonia can contribute to sleep-disordered breathing; sleep hygiene and directed sleep studies reduce daytime symptoms. NCBI

9) Oral & dental care. Mucosal hamartomas and macroglossia can affect oral health; routine dentistry plus surgical input when needed maintains function. NCBI

10) Activity safety guidance. Teach families to watch for sudden changes (new mass, bleeding, rapid head growth, focal neurologic signs) and to seek timely care. NCBI

11) Reproductive counseling. Autosomal-dominant inheritance means a 50% chance to pass on a PTEN variant; discuss prenatal or preimplantation options. NCBI

12) Care coordination. A single point of contact (genetics clinic or primary care) to synchronize specialists, testing intervals, and insurance approvals reduces delays and duplications. Nature

---

Medicines used in BRRS care

There are currently no FDA-approved drugs specifically for Bannayan–Riley–Ruvalcaba syndrome or PTEN hamartoma tumor syndrome. When medicines are used, they treat associated conditions (e.g., anemia from bleeding polyps, thyroid disease, seizures, pain) and follow their usual FDA-approved indications. Some agents (e.g., sirolimus) are studied off-label in related overgrowth/vascular-anomaly states, but decisions must be specialist-led. NCBI+1

Below are 10 representative, condition-specific medications frequently used around BRRS care, with FDA-label anchors to help clinicians verify dosing/safety. (I can expand to a larger annotated list if you want a full pharmacopeia section.)

1. Levothyroxine — for hypothyroidism when present; dosed by weight/TSH. FDA labeling provides dosing, monitoring, and drug interaction cautions. (Label: accessdata.fda.gov)

2. Levetiracetam — for seizures if they occur; widely used due to limited interactions and titratability. (FDA label)

3. Valproate — an alternative antiepileptic; label emphasizes hepatic risk and teratogenicity—specialist oversight essential. (FDA label)

4. Propranolol — for selected problematic infantile hemangiomas/vascular anomalies; label includes dosing and monitoring for hypoglycemia/bradycardia. (FDA label)

5. Omeprazole (PPI) — for reflux, ulcer prophylaxis around endoscopic polypectomy, or GI bleeding risk as clinically indicated. (FDA label)

6. Oral iron (e.g., ferrous sulfate) — to treat iron-deficiency anemia from GI blood loss; follow label for dosing and GI side-effect mitigation. (FDA label)

7. Tranexamic acid — short-term use may be considered in mucosal bleeding episodes under specialist care; label warns on thrombosis risk. (FDA label)

8. Topical anesthetics (e.g., lidocaine) — peri-procedural comfort for skin or mucosal lesion care; check label max doses to avoid toxicity. (FDA label)

9. Acetaminophen — first-line analgesic; label guidance on maximum daily dose and liver safety. (FDA label)

10. Sirolimus (specialist-led, off-label in this context) — mTOR pathway inhibitor explored for hamartoma/vascular anomaly symptom control; FDA-approved for transplant with detailed monitoring requirements and drug interactions; off-label use should occur in expert centers or trials. (FDA label; research context)

(Because each FDA label is a distinct document on accessdata.fda.gov, editors usually link individual labels directly in the web version for compliance and easy verification.) NCBI

---

Dietary molecular supplements

No supplement treats BRRS itself. But in everyday care—especially with bowel polyps and anemia—dietary adjuncts can help correct deficiencies under clinician guidance:

• Elemental iron (if iron-deficiency anemia): improves hemoglobin; GI side effects can be reduced by dose splitting or using newer formulations. Evidence and dosing follow standard anemia care. NCBI

• Vitamin D (if low): supports bone health, especially if mobility is limited; check levels and replete per guidelines. NCBI

• Vitamin B12 & folate (if low): correct megaloblastic anemia or neuropathy risks; monitor levels. NCBI

• Calcium (dietary first): supports bone mineralization, especially if long-term PPI therapy is used. NCBI

• Omega-3 fatty acids: general cardiometabolic support; avoid around procedures if bleeding risk is high. NCBI

Always individualize supplements to lab-documented needs; avoid mega-doses and check interactions with prescription drugs.

---

Immunity boosters, regenerative, and stem-cell drugs

At this time, there are no approved immune-boosting or stem-cell therapies for BRRS/PHTS. Claims to regenerate PTEN function with drugs or stem cells are experimental and should not be used outside a clinical trial at an expert center. Families can ask about trials through genetics or oncology clinics. NCBI

---

Procedures and surgeries

• Endoscopic polypectomy for symptomatic intestinal hamartomas (bleeding, anemia, pain, obstruction risk). Removes polyps, reduces bleeding and anemia; repeat may be necessary. NCBI

• Excision of symptomatic lipomas or mucocutaneous lesions when painful, function-limiting, or cosmetically distressing. Pathology confirms benign nature. NCBI

• Thyroid surgery (lobectomy/thyroidectomy) if suspicious nodules or cancer are confirmed by imaging/FNA and expert review. Nature

• Vascular anomaly interventions (e.g., sclerotherapy, laser, or resection) in specialized centers for pain, bleeding, or functional compromise. Nature

• Gynecologic procedures (biopsy, hysteroscopy) when endometrial pathology is suspected based on symptoms and risk profile. Nature

---

Practical prevention tips

1. Keep a written surveillance calendar (thyroid, breast, skin, renal, etc.). Nature

2. Know your baseline: head circumference (children), hemoglobin/iron, thyroid function, skin and oral exam findings. NCBI

3. Sun protection daily and skin self-checks monthly. Nature

4. Healthy weight and activity—joint-friendly exercise to support balance and bone health. NCBI

5. Vaccinations per national schedule; discuss extra needs if on immunosuppressants like sirolimus. NCBI

6. GI attention to new bleeding, black stools, or iron-deficiency symptoms. NCBI

7. Thyroid awareness: hoarseness, neck swelling, or fast-growing nodules deserve prompt review. Nature

8. Breast self-awareness and prompt evaluation of new lumps/changes; follow enhanced screening plans. facingourrisk.org

9. Medication checkups: review all meds/supplements for interactions, especially if an mTOR inhibitor is used. NCBI

10. Family cascade testing so relatives get appropriate screening. NCBI

---

When to see a doctor urgently

• New or rapidly changing mass, unexplained bleeding, black/tarry stools, or fainting.

• Persistent headaches, vomiting, seizures, or focal weakness.

• Neck lump, voice changes, or trouble swallowing.

• Breast changes (new lump, skin dimpling, nipple retraction, discharge).

• Skin lesion that changes color/shape or bleeds.
  These are general “red flags”; care teams personalize thresholds based on history. NCBI+1

---

What to eat and what to avoid

• Emphasize: iron-rich foods (legumes, leafy greens, lean meats) with vitamin-C-rich sides to enhance absorption; fiber-rich whole foods for bowel regularity; adequate protein for wound healing; calcium and vitamin-D-containing foods for bones. NCBI

• Limit/avoid: alcohol excess (cancer risk), ultra-processed foods high in sodium/sugar (weight, BP, reflux), very low-fiber patterns if constipation is a problem. If you have active GI bleeding or are peri-procedure, follow your gastroenterologist’s temporary restrictions (e.g., avoiding fish-oil megadoses or NSAIDs). NCBI

---

Frequently asked questions (FAQs)

1) Is BRRS the same as Cowden syndrome?
No. Both are part of PTEN hamartoma tumor syndrome (PHTS). They share PTEN-related biology and cancer-risk management, but their typical clinical pictures differ. NCBI

2) Does everyone with BRRS get cancer?
No. Risk is elevated for certain cancers versus the general population, but not everyone develops cancer. Screening aims to catch problems early. Nature+1

3) How common is BRRS?
It is rare; exact prevalence is unknown due to under-recognition and variability. Orpha

4) Can a parent with a PTEN variant have a child without BRRS?
Yes. Each child has a 50% chance to inherit the variant; if they do not, they won’t have PHTS/BRRS. De novo variants also occur. Genetic counseling can help plan. NCBI+1

5) What tests confirm the diagnosis?
PTEN genetic testing (sequencing plus deletion/duplication analysis). Some people have large deletions that require MLPA or similar methods. Orpha+1

6) What is the typical age at diagnosis?
Often infancy or early childhood due to macrocephaly or other features; adults can be diagnosed after a child in the family is tested. MedlinePlus

7) Can diet cure BRRS?
No. Diet supports health and treats deficiencies (like iron) but cannot fix a PTEN variant. NCBI

8) Are there PTEN-targeted drugs?
Not yet for clinical care. Some agents (e.g., mTOR inhibitors) are being studied for symptom control in related overgrowth/vascular anomalies, but they’re not BRRS-approved. Nature

9) How often should screening be done?
Intervals vary by age, organ system, and personal/family history. Work with a genetics-led clinic to build an individualized, written plan. Nature

10) Should children have the same surveillance as adults?
Pediatric guidance differs (e.g., timing of thyroid US) and is being updated as data evolve. Pediatric oncology/genetics clinics should direct this. PMC+1

11) Is pregnancy riskier with BRRS?
Most risks relate to routine obstetric issues and individualized cancer screening. Preconception genetic counseling is recommended. NCBI

12) Are seizures part of BRRS?
They can occur in some patients (e.g., from vascular malformations), but not everyone has them. Neurologic evaluation guides therapy. Default

13) Do lipomas turn into cancer?
Typical lipomas are benign. Rapid change, pain, or firm/irregular masses warrant imaging and specialist review. NCBI

14) Will my child “outgrow” BRRS?
BRRS is lifelong, but supportive therapies, surveillance, and education greatly improve outcomes and independence. NCBI

15) Where can families get reliable information?
GeneReviews, Orphanet, MedlinePlus Genetics, and patient advocacy groups with medical advisory boards. NCBI+2Orpha+2

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 17, 2025.